Abbott (ABT) Q4 FY25 earnings call

Abbott delivered strong Q4 FY25 results, with robust growth in Medical Devices and EPD, and accelerating Core Lab Diagnostics, despite anticipated declines in COVID testing. The company is addressing challenges in its Nutrition business by implementing price and promotion initiatives and launching new products to reignite volume growth, expecting a return to growth in the second half of 2026. Strategic actions, including the Exact Sciences acquisition, position Abbott for sustainable long-term growth.